Purevax RC

RSS

vaccine against feline viral rhinotracheitis and feline calicivirosis

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 30/04/2018

Authorisation details

Product details
Name
Purevax RC
Agency product number
EMEA/V/C/000091
Active substance
attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis and feline calicivirosis
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AH
Publication details
Marketing-authorisation holder
Merial
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
23/02/2005
Contact address
29 avenue Tony Garnier
69007 Lyon
France

Product information

15/01/2015 Purevax RC - EMEA/V/C/000091 - WS-0606

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged eight weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion.

Onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis and calicivirus components.

The duration of immunity is three years after the last re-vaccination.

Assessment history

How useful was this page?

Add your rating